LINC01262

Across TCGA pan-cancer cohorts, LINC01262 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of LINC01262’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where LINC01262 RNA is repressed in tumor relative to normal tissue. In most cancer types LINC01262 is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

KIRC, KICH, and BRCA are the cancer types where LINC01262 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC01262 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	−0.023	.001	9	view →
KICH	All	All	−0.035	<.001	5	view →
BRCA	All	II,III,IV	−0.053	<.001	4	view →
KIRP	All	All	−0.013	.011	3	view →
LUSC	All	All	−0.031	.004	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

LINC01262–KIRC

Open the KIRC breakdown →